Breast Cancer Translational Research Laboratory – JC Heuson, Institut Jules Bordet, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. [email protected] Brain metastasis (BM) are increasingly ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Overall survival in metastatic HER2-positive breast cancer varied by location of brain lesions. Patients with central nervous system (CNS)-only disease had a higher risk of CNS-related death, despite ...

Patients had stable and active brain metastases at baseline in the phase IIIb/IV study. The estimated overall median progression-free survival (PFS) was 17.3 months in patients who received the ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive ...

For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

The annual San Antonio Breast Cancer Symposium was held from Dec. 9 to 12 in San Antonio. Attendees included medical oncologists, radiation oncologists, researchers, and other health care ...